Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
Lead Sponsor:
TaiGen Biotechnology Co., Ltd.
Conditions:
Healthy
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients
Detailed Description
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of Single and Multiple ...
Eligibility Criteria
Inclusion
- East Asian or Caucasian subjects, male or female, and 18 to 65 years of age inclusive
- Body mass index (BMI) in the range of 19.0 to 30.0 kg/m2 and body weight ≥ 50 kg inclusive
- In generally good physical and mental health status on the basis of a medical history review, medical evaluation including vital signs and physical examination, 12-lead ECG, and laboratory results at screening
- For females, one of the following criteria must be fulfilled:
- At least 1 year post menopausal, or
- Surgically sterile, or
- Willing to use a double barrier method \[intrauterine device (IUD) plus condom, spermicidal gel plus condom\] of contraception from screening until 30 days after the last dose of study drug
- Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from screening until 30 days after the last dose of study drug
- Willing to abstain from caffeine- or xanthine-containing beverages, including coffee and tea, alcohol, grapefruit juice, and Seville oranges during the stay-on-site period
- Willing and able to provide written informed consent
Exclusion
- Positive serological test for IgM anti-HAV antibody, HBsAg or anti-HCV antibody at screening
- Positive ELISA test for HIV-1 or HIV-2 at screening
- Any abnormal laboratory values at screening: Hemoglobin (Hb) \<12.0g/dL for women and \<13.0g/dL for men, white blood cell count (WBC) \<3,000 cells/mm3, absolute neutrophil count \<1,500 cells/mm3, platelet count \<100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin
- ≥ 1.5 x ULN, INR (International Normalized Ratios for prothrombin time) ≥ 1.5 xULN
- Any abnormal laboratory values that are considered clinically significant by the Investigator at screening
- QTcF greater than 450 msec for females and 430 msec for males at screening
- History of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome
- History of seizures, epilepsy, cardiovascular, diabetes or cancer (except basal cell carcinoma)
- History or family history of prolonged QT interval or family history of sudden cardiac death at a young age
- History of drug allergy or hypersensitivity, especially to sulfa drugs
- History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational or narcotic drug use within 6 months prior to first dose of study drug administration
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of a psychiatric illness, or have any history of suicide attempt or depression
- Anemia or blood/plasma donation within 30 days prior to first dose of study drug administration
- Pregnant or breast-feeding
- Use of tobacco or nicotine-containing products within 30 days prior to first dose of study drug administration
- Use of concomitant medication, including herbal remedies, and dietary supplements (except for paracetamol/acetaminophen, ibuprofen and hormonal contraceptives) within 14 days prior to first dose of study drug administration
- Received any other investigational drug within 30 days prior to first dose of study drug administration
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT01523990
Start Date
October 1 2011
End Date
July 1 2013
Last Update
December 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
WCCT
Cypress, California, United States, 90630